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Summary
Coronary heart disease (CHD) is one of the most common types of organ lesions caused by atherosclerosis, in which CD4
1 CD25 1 forkhead box protein 3 ( FoxP3 1 ) regulatory T cells (T reg ) play an atheroprotective role. However, T reg cell numbers are decreased and their functions are impaired in atherosclerosis; the underlying mechanisms remain unclear. CD31 plays an important part in T cell response and contributes to maintaining T cell tolerance. The immunomodulatory effects of CD31 are also implicated in atherosclerosis. In this study, we found that decreased frequencies of the Tr cells might be because of attenuated SHP2 and STAT-5 activation. These data indicate that decreased frequencies and impaired functions of the CD31 1 Tr subpopulation associated with decreased FoxP3 expression give rise, at least in part, to T reg cell defects in CHD patients. Our findings emphasize the important role of the CD31
Introduction
Coronary atherosclerotic heart disease (CHD) is one of the most common types of organ lesions caused by atherosclerosis. Atherosclerosis is a chronic inflammatory disease, in which abundant immune cells are involved [1] . T cells present during all stages of the disease are essential to the development of atherosclerotic plaque [2] . Among them, T helper type 1 (Th1)/Th17-mediated proinflammatory responses aggravate atherosclerosis while regulatory T cells (T reg ) play a key atheroprotective role by limiting inflammation and counterbalancing plaque formation.
Human CD4
1 CD25 1 T reg cells can suppress activation of a variety of immune cells mediated through cell-to-cell contacts and/or secretion of inhibitory cytokines such as transforming growth factor (TGF)-b1 and interleukin (IL)-10 to prevent self-reactive immune responses and maintain dominant self-tolerance [3] [4] [5] [6] . Forkhead box transcription factor protein 3 (FoxP3) is a molecular marker of and the cell lineage specification factor for CD4 1 patients with coronary atherosclerosis report T reg cell functional impairments associated with an obvious decrease in their numbers, FoxP3 levels and T reg -related cytokines (TGF-b1 and IL-10) [11] [12] [13] . Animal experiments also confirm that increasing T reg cell numbers and improving their functions would greatly reduce atherosclerotic plaque [14, 15] . However, the causes and mechanisms underlying T reg cell defects in atherosclerosis remain unclear. CD31, also known as platelet endothelial cell adhesion molecule-1 (PECAM-1), a transmembrane homophilic and inhibitory receptor containing two immunoreceptor tyrosine inhibitory motifs (ITIMs) located in its cytoplasmic tails, is expressed by endothelial cells, platelets and immune cells and is regarded generally as an endothelial marker. Interestingly, recent studies reveal an important role of this molecule in the regulation of T cell responses. During the interactions of immune cells, CD31 signal transduction is induced by homophilic engagements and is mediated through recruitment and activation of tyrosine-phosphatases, such as SH2-containing inositol 5 phosphatase (SHIP), Src homology region 2 domain-containing phosphatase-1 (SHP1) and SHP2 by its ITIMs, and CD31 deficiency is associated with excessive immunoreactivity, which means uncontrolled immune response, and susceptibility to cytotoxic killing, which means decreased cell viability [16] . Under immunological stress, lack of CD31 accelerates and aggravates T cell-mediated inflammation in mice [17, 18] . The immunoregulatory role of CD31 has also been implicated in atherosclerosis. CD31 gene knock-out results in an enhanced atherosclerotic lesion formation in LDL receptor-deficient mice [19] . Decreased CD31 1 T cells are correlated positively with the occurrence of atherothrombosis in mice [20] and of abdominal aortic aneurysm in patients [21] .
Furthermore, over-expression of a CD31 receptor globulin leads to the induction of T cell hyporesponsiveness and impairment of T cell activation, which indicates that CD31 signalling may contribute to the establishment and maintenance of T cell tolerance [22] . It is well known that T reg cells play a key role in maintaining self-tolerance, preventing the development of autoimmunity. Although a direct link between CD31 expression and T reg cell function has not yet been reported, CD31 signal activation has been shown to increase T reg cell proportion in vivo [23] , and the tyrosinephosphatase SHP2 recruited by CD31 ITIMs can promote T reg cell generation mediated by the Grb-2 associated binderextracellular-regulated kinase-mitogen-activated protein kinase (Gab-Erk-MAPK) pathway [24] . Studies have also suggested a relationship between CD31 expression and T reg cell function in atherosclerosis. Administration of a CD31-derived peptide prevents atherosclerotic progression in apolipoprotein E knock-out mice by driving enrichment of the T reg cell compartment at the expense of the effector T (T eff ) cell compartment [23] . Restoring the CD31 signal contributes to modulating T cell activation and improves experimental atherosclerosis via enrichment of circulating T reg cells [25] . In addition, naive T reg cells contribute to maintaining FoxP3 expression of T reg cells after expansion in vitro [26] . It is worth noting that CD31 expression level in naive T reg cells is clearly higher than in memory T reg cells [27] . Thus, it presents the possibility that there is some correlation between CD31 and FoxP3, and CD31 may affect T reg functions on the basis of this association in the development of atherosclerosis. In this study, we investigate the role of the CD31 1 subpopulation in T reg cells as well as the correlation with FoxP3 expression in patients with CHD or in healthy individuals. For intracellular detection of cytokines, PBMCs from healthy individuals or CHD patients were incubated for 5 h and stimulated concurrently with or without cell stimulation cocktail (containing phorbol 12-myristate 13-acetate and ionomycin; eBioscience) at a dilution of 1 : 500, as well as protein transport inhibitor cocktail (containing brefeldin A and monensin; eBioscience) at a dilution of 1 : 500. The resulting cells were first surface-stained with antibodies against CD4-eFluor V R 450 (OKT4), CD25-PE-Cy7 (BC96) and CD31-APC-eFluor V R 780 (WM59) (eBioscience), then intracellular-stained with antibodies against FoxP3-Alexa Fluor V R 488 (236A/E7) (eBioscience), TGF-b1-PerCP-Cy TM 5.5 (TW4-2F8) and IL-10-PE (JES3-19F1) together with their isotype controls (BD Bioscience) using the fixation/ permeabilization kit according to the manufacturer's instructions. Secretion levels of TGF-b1 and IL-10 in different cell subsets were detected using a flow cytometer.
Materials and methods

Patients and controls
To analyse the phosphorylation levels of SHP2, signal tranduser and activator of transcription (STAT)25 and STAT-3, PBMCs from healthy individuals or CHD patients were left unstimulated or were stimulated for 15 min with 5 lg/ml anti-CD3 and 5 lg/ml anti-CD28 antibodies (eBioscience) for SHP2, 100 ng/ml IL-2 (R&D Systems, Minnneapolis, MN, USA) for STAT-5 and 100 ng/ml IL-6 (Peprotech, Rocky Hill, NJ, USA) for STAT-3, respectively. Cells were then fixed with 1% paraformaldehyde, permeabilized with 1 ml of ice-cold methanol for 30 min on ice and stained with antibodies against CD4-eFluor V R 450 (OKT4), CD25-PE-Cy7 (BC96), CD31-APC-eFluor V R 780 (WM59) and FoxP3-Alexa Phosphorylation levels of SHP2, STAT-5 and STAT-3 in different cell subsets were analysed by flow cytometry (FCM). (total 1 3 10 5 cells/well) under the same culture conditions described above, and T eff cells in each co-cultured group were pretreated with CFSE staining. After 5 days, T eff cell proliferation was analysed using a flow cytometer.
Cell sorting and functional assays
Statistical analysis
Data are expressed as mean 6 standard deviation (s.d.). Comparisons between groups were analysed by two-tailed Student's t-test or analysis of variance (ANOVA) test when appropriate. For normally distributed data, differences between groups were evaluated using Tukey's test, and associations were assessed using Pearson's correlation coefficient. For non-normally distributed data, differences between groups were evaluated using the non-parametric Mann-Whitney U-test, and associations were assessed using a Spearman's rank correlation coefficient. A value of P < 0Á05 was considered statistically significant. All statistical analyses were performed using GraphPad Prism (version 5Á0).
Results
Clinical characteristics of CHD patients and healthy individuals
A cohort of 71 patients with CHD was included in this study and divided into SAP and ACS subgroups, according to the clinical diagnosis. The baseline characteristics of enrolled patients were well-matched among groups and are summarized in Table 1 . Among the groups, no significant differences were observed with regard to the demographic and risk factor information, such as gender, age, smoking, hypertension and diabetes mellitus, as well as the biochemical parameters, including total cholesterol, triglycerides and LDL. However, the other biochemical parameters which contribute to reflect disease activity and severity, such as Hs-CRP, TnI and NT-proBNP, were significantly higher in the ACS group than in the SAP and HC groups. In addition, the differences of baseline characteristics between the overall disease group (CHD 5 SAP 1ACS) and the HC group are compared in Table 1 in order to help further statistical analysis for the following experimental data. No significant differences were observed with regard to the demographic and risk factor information as well as all the biochemical parameters between the two groups.
Decreased frequencies of CD31
1 Tr cells associated with decreased FoxP3 expression in CHD patients To investigate the variation of different T reg cell subsets in CHD patients, we first measured the proportion of total-Tr (
2 ) cells, respectively, from the HC, SAP and ACS groups [28, 30] . As shown in Fig. 1a , the frequencies of total-Tr cells were decreased significantly in ACS patients (3Á7 6 1Á0%) compared with in SAP patients (4Á8 6 1Á4%, P < 0Á05) and the HC group (5Á6 6 1.5%, P < 0Á05), both SAP and HC groups had comparable amounts of total-Tr cells (P > 0Á05). This result was consistent with our previous findings [31, 32] . As shown in Fig. 1b ,c, the frequencies of CD31
1 Tr cells were markedly higher in the HC group (33Á4 6 6Á8%) than in SAP (24Á3 6 6Á4%, P < 0Á05) and ACS patients (20Á1 6 5Á7%, P < 0Á05); in contrast, the frequencies of CD31 2 Tr cells were clearly lower in the HC group (63Á.4 6 7Á5%) than in SAP (74Á6 6 6Á9%, P < 0Á05) and ACS patients (77Á6 6 6Á3%, P < 0Á05), while both the SAP and ACS groups had comparable amounts of
Tr cells (P > 0Á05). In parallel, we analysed FoxP3 expression levels in totalTr, CD31 
Tr and CD31
2 Tr cells, respectively, from the HC, SAP and ACS groups. As shown in Fig. 1d , horizontal comparison found that FoxP3 expression levels of total-Tr cells were higher in the HC group (91Á0 6 2Á6%) than in SAP (82Á3 6 6Á5%, P < 0Á05) and ACS patients (76Á1 6 6Á9%, P < 0Á05). FoxP3 expression levels of CD31
1 Tr cells were also higher in the HC group (92Á8 6 4Á1%) than in SAP (83Á3 6 4Á8%, P < 0Á05) and ACS patients (77Á8 6 9Á5%, P < 0Á05), while no significant differences in FoxP3 expression levels of CD31
2 Tr cells among the HC, SAP and ACS groups were observed (P > 0Á05). Vertical comparison found that FoxP3 expression levels of CD31
1 Tr cells (92Á8 6 4Á1%) were comparable to those of total-Tr cells (91Á0 6 2Á6%, P > 0Á05) but were clearly higher than those of CD31
2 Tr cells (82Á9 6 6Á8%, P < 0Á05) in the HC group; however, no significant differences in FoxP3 expression levels of total-Tr, CD31
1 Tr and CD31 2 Tr cells were observed in the SAP or ACS groups (P > 0Á05). We further analysed the correlation between CD31 and FoxP3 expression levels in total-Tr cells from the HC, SAP and ACS groups. It was demonstrated that CD31 was correlated positively with FoxP3 whether in the HC (r 5 0Á63, P 5 0Á0053), SAP (r 5 0Á71, P 5 0Á0023) or ACS groups (r 5 0Á52, P 5 0Á0246) (Fig. 1e) .
As there were no significant differences between the SAP and ACS groups with respect to the frequencies of CD31
1 Tr or CD31 2 Tr cells and FoxP3 expression levels of three different T reg cell subsets, we merged SAP and ACS into the CHD group in order to elucidate concisely the differences between the healthy population and the whole CHD population, as shown in the CHD histograms of Fig. 1b -e. We then used the CHD group as disease controls 
Tr cells after activation in vitro
We next investigated the phenotypes of total-Tr, CD31
1
Tr and CD31
2 Tr cells before and after activation in vitro. to 94Á6 6 3Á8%). Total-Tr cells were cultured and activated with anti-CD3 and anti-CD28 antibodies for 7 days and showed an increasing trend of cell proliferation (Fig. 2d) . FoxP3 expression levels were maintained stably for 5 days, but decreased on day 7 (Fig. 2e) . The optimal activation time of 5 days was used, and also for the following experiments in vitro, in order to ensure stable phenotypes of T reg cells.
Total-Tr cells (CD4
We found no significant differences in CD31 expression levels of total-Tr, CD31
1 Tr or CD31 Tr cells before (day 0) and after (day 5) cell activation (Fig. 2f) , which indicated that CD31 phenotypes in the three groups of cells had not changed during cell activation. However, FoxP3 expression levels of CD31 2 Tr cells on day 5 were lower than on day 0 and had decreased significantly compared with those of total-Tr and CD31 1 Tr cells on day 5 (Fig. 2g) . Collectively, these data demonstrated stable FoxP3 expression in CD31 (Fig. 3b) . These results suggest that the Decreased secretion levels of TGF-b1 and IL-10 in CD31
1
Tr cells of patients with CHD
It is known that secretion of inhibitory cytokines is one of the important immunoregulatory modes of action for T reg cells [5, 6] . Therefore, we analysed the intracellular TGF-b1 and IL-10 secretion profiles of CD31 1 Tr or CD31 2 Tr cells from patients with CHD or healthy controls (HC). As shown in Fig. 4a (upper right), whether stimulated with (ST) or without (US) cell stimulation cocktail, decreased TGF-b1 secretion levels in CD31 1 Tr cells were observed in CHD patients compared with the HC group, while no significant differences in TGF-b1 secretion levels in CD31
2 Tr cells were observed between the CHD and HC groups. We also analysed the differences in TGF-b1 secretion levels between CD31 1 Tr and CD31
2
Tr cells in the CHD or HC groups, as shown in Fig. 4a (below right) . In the HC group, higher TGF-b1 secretion levels were observed in CD31
1 Tr cells than in CD31
Tr cells. However, in CHD group, the differences between the two groups of cells were especially attenuated by US treatment.
Furthermore, similar results were also obtained with detection of IL-10 secretion levels in the same conditions. That is, reduced IL-10 secretion levels of CD31
1 Tr cells were observed by ST treatment in CHD patients compared with the HC group (Fig. 4b, upper right) ; comparison of 
Tr and CD31
2 Tr cells showed statistical differences in the HC group, but not in the CHD group (Fig. 4b, below right) . In brief, we confirmed enhanced secretion of TGF-b1 and IL-10 in CD31 with CHD or healthy individuals may be affected, related partly to different activation of SHP2, STAT-5 or STAT-3.
As shown in Fig. 5a , significant changes in phospho-SHP2 (p-SHP2) levels were observed only in CD31 Tr cells were cultured in vitro by stimulation with precoated anti-CD3 and soluble anti-CD28 antibodies for 5 days, respectively, in which the expression levels of CD31 (f) and FoxP3 (g) were determined before (day 0) and after (day 5) activation. Representative FCM Zebra plots are shown. Data are mean 6 standard deviation (s.d.), n 5 5. *P < 0Á05 versus day 0, one-way analysis of variance (ANOVA) test used in (e). *P < 0Á05, two-way ANOVA test used in (f) and (g).
in the CHD group compared with the HC group and greater decreased p-STAT-5 levels were observed in CD31
1 Tr cells than in CD31 2 Tr cells (Fig. 5b, upper right) . As shown in However, we found no significant differences in phospho-STAT-3 (p-STAT-3) levels between CD31
1 Tr and CD31 2 Tr cells whether with (ST) or without (US) IL-6 stimulation and whether in CHD patients or in the HC group (Fig. 5c ), which implied no close relationship between p-STAT-3 and CD31 in T reg cells.
Discussion
In this study, we analysed and compared the frequencies and functions of three different subsets of T reg cells; that is, totalTr, CD31 1 Tr and CD31 2 Tr cells isolated from PBMCs from healthy individuals or patients with CHD. We also preliminarily investigated changes in the phosphorylation levels of SHP2 (associated with CD31 activation) and STAT-5/3 (associated with FoxP3 transcription) in different cell groups. Our study demonstrated that the decreased frequencies and impaired functions of CD31 1 Tr cells were associated with decreased FoxP3 expression in CHD patients, in which SHP2 and STAT-5 activations were attenuated.
CHD is one of the most common diseases seriously harmful to human health, and one of the leading causes of death in China in recent years [37] . Atherosclerosis is the pathophysiological basis of CHD, and prevention and treatment of atherosclerosis are basic strategies for CHD therapy. In atherosclerotic plaques, Th1 and Th17 cells aggregate and produce high levels of inflammatory cytokines such as IFN-g and IL-17 [38, 39] , while T reg cells play an anti-inflammatory role through cell-to-cell contacts and/or secretion of inhibitory cytokines such as TGF-b1 and IL-10 [3] [4] [5] [6] . Furthermore, studies have found that Th17/T reg imbalance occurs in atherosclerosis and its clinical complications such as ACS [31, 32, 40, 41] . The imbalance between immune inflammation and immune regulation contributes to the development of atherosclerosis. T reg cell numbers are decreased and their functions are impaired in atherosclerosis; however, the underlying mechanisms remain unclear. Recently, CD31 has been found to be involved in T cell responses and contribute to T cell tolerance, and the immunoregulatory role of CD31 has been implicated in atherosclerosis. However, there are few studies concerning the direct link between CD31 expression and T reg cell function in atherosclerosis and its vascular complications such as CHD. Thus, in this study we investigated the role of the CD31 1 subpopulation in T reg cells as well as the correlation with FoxP3 expression in patients with CHD or in healthy individuals. Our main purpose was to observe the changes in the quantity and quality of CD31 1 subpopulation in T reg cells under physiological or pathological conditions and conduct a brief investigation on the molecular mechanisms underlying these changes in order to elucidate the importance of CD31 1 subpopulation in T reg cells. We first confirmed decreased frequencies of CD31 Tr cells may also contribute to enhance their immunosuppression in vitro. Having known that increasing CD31 expression helps to improve T reg cell survival [16, 23, 24] , this may account partly for good proliferation of CD31
1 Tr cells in vitro. Unfortunately, we are unable to repeat the above-mentioned cell culture and functional assays in vitro in CHD patients due to the lack of sufficient blood samples.
Because T reg cells regulate T eff cell proliferation not only via cellular direct contacts, but also via secretion of inhibitory cytokines, we analysed the secretion levels of TGF-b1 and IL-10 in different subsets of T reg cells from healthy individuals or CHD patients. We demonstrated elevated secretion levels of TGF-b1 and IL-10 in CD31
1 Tr cells compared with CD31
2
Tr cells with impaired secretion of these cytokines in CD31
1 Tr cells present in CHD patients. Results from intracellular cytokine detection revealed that CD31
1 Tr cells had functional impairment in addition to their lower frequencies in patients with CHD.
The key role of FoxP3 in regulating the suppressor function of T reg cells has been well documented [7, 9, 42] . In this study, we observed decreased FoxP3 expression as well as decreased TGF-b1 and IL-10 secretion in CD31 1 Tr cells of CHD patients, and considered that the former possibly accounted for the latter based on the findings of others, that attenuated FoxP3 expression leads to impaired secretion of inhibitory cytokines and subsequent suppressor function of T reg cells [43, 44] . Further analysis revealed that the levels of p-SHP2 and p-STAT-5 were both reduced in CD31 1 Tr cells of CHD patients, suggesting that decreased FoxP3 expression in CD31
1 Tr cells might be because of attenuated SHP2 and STAT-5 activation. Because SHP2 phosphorylation is likely to reflect CD31 activation, this result indicates that the attenuated CD31 signal is also present in CD31
1
Tr cells of CHD patients. However, no close relation between p-STAT-3 and CD31 in T reg cells was found in this study. Thus, we considered that the CD31 signal might affect FoxP3 expression associated with activation of SHP2 and STAT-5 in CD31
1 Tr cells.
In summary, these data indicate that disorders of the CD31 1 subpopulation in CD4 (Table 1) . However, we did not analyse specific drug use by different patients, in view of the majority of them taking similar anti-CHD medications including anti-platelet drugs, statins, angiotensinconverting enzyme inhibitors and b-blockers. To our knowledge, and beyond the disease context of CHD, our findings emphasize the important role of the CD31 1 subpopulation in maintaining normal T reg cell function, and propose a novel explanation for impaired immunoregulation of T reg cells in CHD.
